Cough Suppressant Drugs Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation

Cough Suppressant Drugs Market Analysis | CMI


Read here the latest updates on the Cough Suppressant Drugs Market Analysis published by CMI team – PowerPoint PPT presentation

Number of Views:1


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Cough Suppressant Drugs Market Analysis | CMI

  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Cough Suppressant Drugs Market, by Disease Type
    (Dry Cough and Wet Cough), by Drug Type
    (Dextromethorphan, Codeine, Noscapine,
    Butamirate, Benzonatate, Pholcodine, and Others),
    by Product Type (Over-the-counter (OTC) and
    Prescription Drug), by Age Group (Pediatric and
    Adult), by Dosage Form (Syrup, Tablet, and
    Others), by Distribution Channel (Hospital,
    Retail Pharmacy, Online Pharmacy, and Others),
    and Region (North America, Latin America, Europe,
    Asia Pacific, Middle East, and Africa) - Size,
    Share, Outlook, and Opportunity Analysis, 2018
  • The global cough suppressant drugs market size
    was valued at US 1100.4 Mn in 2017 and is
    expected to witness a CAGR of 3.7 during the
    forecast period (2018 2026).

Market Drivers
  • Frequent approvals and launch of new cough
    suppressant drugs and high prevalence of cough is
    expected to drive the market growth
  • In March 2018, Perrigo Company plc. received the
    FDA approval for the brand OTC equivalent of
    Mucinex DM Maximum Strength (Guaifenesin and
    Dextromethorphan Hydrobromide Extended-release
    Tablets, 1200 mg/60 mg). Mucinex DM Maximum
    Strength is indicated to control coughs and to
    break up mucus, making coughs more productive.
    Approval and launch of such new drugs in the
    market is expected to drive the Cough Suppressant
    Drugs Market growth over the forecast period.
  • High prevalence of cough is also expected to be a
    major factor for rising demand for cough
    suppressant drugs, which drives the market
    growth. For instance, according to the data
    published by the National Center for
    Biotechnology Information in 2014, cough is the
    most common reason for visits to primary care
    physicians globally, accounting for around 8 of
    all consultations. According to the same source,
    the annual prevalence of cough in the general
    population is reported as approximately 1033

  • North America is expected to hold dominant
    position, owing to frequent approvals of new
    cough suppressant drugs by FDA
  • North America cough suppressant market is
    expected to show good growth over the forecast
    period, owing to frequent approvals to novel
    drugs by the FDA. For instance, in 2015, Vernalis
    plc and Tris Pharma Inc. received the U.S. Food
    and Drug Administration (FDA) approval for the
    New Drug Application (NDA) for Tuzistra XR
    (codeine polistirex and chlorpheniramine
    polistirex) extended-release oral suspension,
    CIII (DEA Schedule III). Tuzistra XR is a
    codeine-based extended-release oral suspension
    for cough-cold treatment.

Figure 1. Global Cough Suppressant Drugs Market
Share () Analysis, By Region, 2026
Key Development
  • Key players in the market are involved in
    strategic mergers and partnerships, in order to
    develop, manufacture, and sell novel cough
    suppressant drugs and to gain major market share.
  • For instance, in 2015, Tris Pharma, Inc. entered
    into a license, supply, and distribution
    agreement with Pfizer Consumer Healthcare (a part
    of Pfizer Inc.). According to the agreement,
    Pfizer Consumer Healthcare will commercialize
    Tris extended release dextromethorphan cough
    syrup under the Robitussin Brand. In exchange,
    Tris will provide the U.S. branded rights to its
    protected intellectual property for an extended
    release dextromethorphan formulation to Pfizer
    Consumer Healthcare and Tris will receive an
    upfront payment, milestone payments, and
    sales-based royalties.

Figure 2. Global Cough Suppressant Drugs Market
Share () Analysis, By Distribution Channel, 2026
Market Opportunities
  • Various new players are entering lucrative cough
    suppressant drugs market by partnering with other
    manufacturers. For instance, in November 2018,
    Aytu BioScience, Inc., a specialty pharmaceutical
    company, entered into the cough suppressant drugs
    market with an exclusive license of FDA-approved
    Tuzistra XR from Tris Pharma Inc. Along with
    Tuzistra XR, Aytu BioScience, Inc. also has a
    licensed complementary antitussive product with
    pending FDA approval.

Market Restraints
  • However, stringent regulations against the use of
    cough suppressant is expected to affect the
    global cough suppressant drugs market growth over
    the forecast period.
  • For instance, in February 2018, the Therapeutic
    Goods Administration reclassified codeine as
    prescription only medicine in Australia, which
    was previously available as over-the-counter
    medication. This reclassification was made, as
    regular use of medicines containing codeine may
    lead to its addiction.
  • In January 2018, the U.S. Food and Drug
    Administration made safety labeling changes to
    limit the use of codeine or hydrocodone
    containing prescription opioid cough and cold
    medicines in children younger than 18 years old
    to protect kids from serious risks of opioid
    ingredients containing cough treatment drugs.
    After the safety labeling changes, these products
    will no longer be indicated for treatment of
    cough in pediatric population and will be labeled
    for use only in adults aged 18 years and older.

Key Players
  • Key players operating in the global cough
    suppressant drugs market include Perrigo Company
    plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc.,
    Aytu BioScience, Inc., Acella Pharmaceuticals
    LLC, Mayne Pharma Inc., Taro Pharmaceutical
    Industries Ltd., Amneal Pharmaceuticals LLC,
    Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//